16 completed, 2 active not recruiting, 2 approved for marketing, 2 not yet recruiting. 9 Not applicable, 8 Phase 2, 4 Phase 1, 3 Early Phase 1.
Follow TheraSphere: new trials by email Literature Review of TheraSphere trials Research Report on TheraSphere
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. TheraSphere - Hepatocellular Carcinoma (HCC) | Not yet recruiting | Boston Scientific Corporation | 140 | 2027-01-01 | 2026-10-01 | |
| A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer TheraSphere - Gastrointestinal Cancer | Not applicable | Not yet recruiting | Centre Georges Francois Leclerc | 18 | 2026-10-01 | 2026-05-13 |
| Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria TheraSphere - Hepatocellular Carcinoma (HCC), Radioembolization | Phase 2 | Recruiting | Seoul National University Hospital | 100 | 2025-03-11 | 2026-08-20 |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial Angiogram, Biospecimen Collection, Computed Tomography - Stage I Renal Cell Cancer, Stage II Renal Cell Cancer | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 25 | 2024-12-26 | 2026-08-21 |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE) - Hepatocellular Carcinoma (HCC) | Phase 2 | Active not recruiting | AstraZeneca | 58 | 2024-02-13 | 2026-09-21 |
| Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver Therasphere - Transarterial Radioembolization | Completed | Ankara University | 202 | 2024-01-15 | 2024-04-24 | |
| Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Atezolizumab, Biopsy, Cabozantinib S-malate - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2022-12-10 | 2022-12-14 | |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer Atezolizumab, Therasphere, XELOX - Metastatic Colorectal Cancer, pMMR | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 52 | 2020-10-07 | 2023-08-18 |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2019-10-10 | 2026-05-22 |
| Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) TheraSphere - Hepatocellular Carcinoma | Completed | Boston Scientific Corporation | 1247 | 2019-03-13 | 2025-07-23 | |
| Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection Nivolumab, Yttrium Y 90 Glass Microspheres - Hepatocellular Carcinoma | Early Phase 1 | Terminated | Northwestern University | 2 | 2019-02-07 | 2024-02-21 |
| Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres - Primary Malignant Liver Neoplasm | Not applicable | Completed | Stanford University | 42 | 2017-02-15 | 2022-01-10 |
| A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC TheraSphere - Hepatocellular Carcinoma | Completed | Boston Scientific Corporation | 209 | 2016-10-31 | 2021-04-21 | |
| Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres - Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma | Phase 1 | Completed | Northwestern University | 27 | 2016-07-01 | 2022-01-25 |
| TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer TheraSphere - Liver, Cancer of, Non-Resectable | Not applicable | Completed | Methodist Health System | 187 | 2014-05-22 | 2021-11-11 |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease TheraSphere, Everolimus, Phone Call - Liver Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2014-05-01 | 2014-07-22 | |
| Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib - Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2013-09-13 | 2021-12-30 |
| Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Early Phase 1 | Terminated | Case Comprehensive Cancer Center | 6 | 2012-12-01 | 2016-03-10 |
| Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer TheraSphere - Unresectable Hepatocellular Carcinoma | Not applicable | Completed | Boston Scientific Corporation | 526 | 2012-03-01 | 2023-11-08 |
| Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer TheraSphere - Colorectal Cancer Metastatic | Not applicable | Completed | Boston Scientific Corporation | 428 | 2012-01-01 | 2022-03-29 |
Showing 20 of 30. Sign in to see all of them.
Carcinoma, Hepatocellular (18) · Liver Neoplasms (6) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Renal Cell (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Recurrence (1) · Sarcoma (1) · Splenomegaly (1) · Uveal Melanoma (1)
Boston Scientific Corporation (6) · M.D. Anderson Cancer Center (4) · Northwestern University (3) · OHSU Knight Cancer Institute (2) · Stanford University (2) · Ankara University (1) · AstraZeneca (1) · Case Comprehensive Cancer Center (1) · Centre Georges Francois Leclerc (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · Jonsson Comprehensive Cancer Center (1) · Methodist Health System (1) · Ohio State University Comprehensive Cancer Center (1) · Rocky Mountain Cancer Centers (1)
United States (21) · France (6) · Germany (3) · Italy (3) · South Korea (3) · Belgium (2) · Canada (2) · Netherlands (2) · Singapore (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Austria (1) · China (1) · Poland (1)
Armeen Mahvash (2) · Laura Kulik, MD (2) · Riad Salem, MD (2) · Adel Kardosh, M.D., Ph.D. (1) · Ahmed O Kaseb (1) · Andrei Iagaru (1) · Aparna Kalyan, MBBS, FRACP (1) · Colette Shaw, MD (1) · Daniel Yung-Ho Sze (1) · Dennise Carter, MD (1) · Etienne Garin, MD (1) · Hugo de Jong, PhD (1) · Jin Woo Choi, MD, PhD (1)
PMID 23703789, PMID 24681342, PMID 25847227, PMID 29329568, PMID 30111528, PMID 30664496, PMID 33443618, PMID 34527608, PMID 34541864, PMID 34796373, PMID 35394152, PMID 37698645, PMID 38985849, PMID 39331131, PMID 41276366, PMID 41903993, PMID 42023169, PMID 42209817
P30CA016672 (3), P30CA060553 (2)